<DOC>
	<DOC>NCT01779453</DOC>
	<brief_summary>This study will assess the safety, atorvastatin pharmacokinetics, and LDL-C lowering efficacy of ETC-1002 versus placebo in hypercholesterolemic subjects on background therapy of atorvastatin 10 mg.</brief_summary>
	<brief_title>A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>For subjects on current daily statin therapy LDLC 100220 mg/dL and triglycerides &lt;350 mg/dL (prior to switching to sponsor provided atorvastatin 10 mg/day and stopping all other lipidregulating drugs and supplements) at the S1 Visit, For subjects not on current daily statin therapy LDLC ≥ 110 mg/dL and ≤ 220 mg/dL Acute significant cardiovascular disease Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Atorvastatin</keyword>
	<keyword>Drug-drug interaction</keyword>
	<keyword>Combination therapy</keyword>
</DOC>